Hyundai Bio

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • Referred to financial risk management details in consolidated financial statements note 34
• • No explicit quantitative foreign exchange exposure or sensitivity disclosed

Management Discussion & Analysis

• • Revenue KRW 3.52B (-76.6% YoY), operating loss KRW 18.16B (turn from KRW 0.83B profit), net loss KRW 22.13B (up from KRW 6.93B loss)
• • Revenue decline driven by absence of previous technology licensing sales of KRW 9.1B, plus soaring clinical trial R&D expenses

Business Overview

• • Core revenue from bio cosmetics and anti-hair loss products, 2025 sales KRW 3.52B, 96% domestic market share
• • New launch of cosmetic line 'Dr.BRID C' with completed domestic online market test and US Amazon release in FY2025

What are the latest Hyundai Bio DART filings in 2026?

Hyundai Bio (KRX code 048410) has filed an annual report on March 30, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Hyundai Bio file its most recent annual report?

Hyundai Bio filed its most recent annual report on March 30, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Hyundai Bio's KRX stock code?

Hyundai Bio's KRX stock code is 048410. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 048410 to look up all Hyundai Bio disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Hyundai Bio file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Hyundai Bio.

Where can I find Hyundai Bio financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Hyundai Bio annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.